Wikipedia

Interferon type I

(Redirected from Alpha interferon)
Not to be confused with Interferon type II.

The type-I interferons (IFN) are cytokines which play essential roles in inflammation, immunoregulation, tumor cells recognition, and T-cell responses. In the human genome, a cluster of thirteen functional IFN genes is located at the 9p21.3 cytoband over approximately 400 kb including coding genes for IFNα (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21), IFNω (IFNW1), IFNɛ (IFNE), IFNк (IFNK) and IFNβ (IFNB1), plus 11 IFN pseudogenes.[1]

Interferon Type I (α/β/δ...)
The molecular structure of human interferon-beta (PDB: 1AU1​).
Identifiers
SymbolInterferons
PfamPF00143
InterProIPR000471
SMARTSM00076
PROSITEPDOC00225
CATH1au1
SCOP21au1 / SCOPe / SUPFAM
CDDcd00095
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1b5l :24-187 1ovi :24-185 2hie :24-186

1itf :24-186 1au1B:22-187 2hif :24-182

1wu3I:22-182

Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains.

Type I IFNs are found in all mammals, and homologous (similar) molecules have been found in birds, reptiles, amphibians and fish species.[2][3]

Sources and functions

edit

IFN-α and IFN-β are secreted by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They stimulate both macrophages and NK cells to elicit an anti-viral response, involving IRF3/IRF7 antiviral pathways,[4] and are also active against tumors. Plasmacytoid dendritic cells have been identified as being the most potent producers of type I IFNs in response to antigen, and have thus been coined natural IFN producing cells.[citation needed]

IFN-ω is released by leukocytes at the site of viral infection or tumors.[citation needed]

IFN-α acts as a pyrogenic factor by altering the activity of thermosensitive neurons in the hypothalamus thus causing fever. It does this by binding to opioid receptors and eliciting the release of prostaglandin-E2 (PGE2).[citation needed]

A similar mechanism is used by IFN-α to reduce pain; IFN-α interacts with the μ-opioid receptor to act as an analgesic.[5]

In mice, IFN-β inhibits immune cell production of growth factors, thereby slowing tumor growth, and inhibits other cells from producing vessel-producing growth factors, thereby blocking tumor angiogenesis and hindering the tumour from connecting into the blood vessel system.[6]

In both mice and human, negative regulation of type I interferon signaling is known to be important. Few endogenous regulators have been found to elicit this important regulatory function, such as SOCS1 and Aryl Hydrocarbon Receptor Interacting Protein (AIP).[7]

Mammalian types

edit

The mammalian types are designated IFN-α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon), IFN-τ (tau), IFN-ω (omega), and IFN-ζ (zeta, also known as limitin).[8][9] Of these types, IFN-α, IFN -ω, and IFN-τ can work across species.[10]

IFN-α

edit

The IFN-α proteins are produced mainly by plasmacytoid dendritic cells (pDCs). They are mainly involved in innate immunity against viral infection. The genes responsible for their synthesis come in 13 subtypes that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. These genes are found together in a cluster on chromosome 9.

IFN-α is also made synthetically as medication in hairy cell leukemia. The International Nonproprietary Name (INN) for the product is interferon alfa. The recombinant type is interferon alfacon-1. The pegylated types are pegylated interferon alfa-2a and pegylated interferon alfa-2b.

Recombinant feline interferon omega is a form of cat IFN-α (not ω) for veterinary use.[10]

IFN-β

edit

The IFN-β proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-β have been described, IFN-β1 (IFNB1) and IFN-β3 (IFNB3)[11] (a gene designated IFN-β2 is actually IL-6).

IFN-ε, -κ, -τ, -δ and -ζ

edit

IFN-ε, -κ, -τ, and -ζ appear, at this time, to come in a single isoform in humans, IFNK. Only ruminants encode IFN-τ, a variant of IFN-ω. So far, IFN-ζ is only found in mice, while a structural homolog, IFN-δ is found in a diverse array of non-primate and non-rodent placental mammals. Most but not all placental mammals encode functional IFN-ε and IFN-κ genes.[citation needed].

IFN-ω

edit

IFN-ω, although having only one functional form described to date (IFNW1), has several pseudogenes: IFNWP2, IFNWP4, IFNWP5, IFNWP9, IFNWP15, IFNWP18, and IFNWP19 in humans. Many non-primate placental mammals express multiple IFN-ω subtypes.

IFN-ν

edit
Not to be confused with Interferon gamma or IFN-γ.

This subtype of type I IFN was recently described as a pseudogene in human, but potentially functional in the domestic cat genome. In all other genomes of non-feline placental mammals, IFN-ν is a pseudogene; in some species, the pseudogene is well preserved, while in others, it is badly mutilated or is undetectable. Moreover, in the cat genome, the IFN-ν promoter is deleteriously mutated. It is likely that the IFN-ν gene family was rendered useless prior to mammalian diversification. Its presence on the edge of the type I IFN locus in mammals may have shielded it from obliteration, allowing its detection.[citation needed]

Interferon type I in cancer

edit

Therapeutics

edit

From the 1980s onward, members of type-I IFN family have been the standard care as immunotherapeutic agents in cancer therapy. In particular, IFNα has been approved by the US Food and Drug Administration (FDA) for cancer. To date, pharmaceutical companies produce several types of recombinant and pegylated IFNα for clinical use; e.g., IFNα2a (Roferon-A, Roche), IFNα2b (Intron-A, Schering-Plough) and pegylated IFNα2b (Sylatron, Schering Corporation) for treatment of hairy cell leukemia, melanoma, renal cell carcinoma, Kaposi's sarcoma, multiple myeloma, follicular and non-Hodgkin lymphoma, and chronic myelogenous leukemia. Human IFNβ (Feron, Toray ltd.) has also been approved in Japan to treat glioblastoma, medulloblastoma, astrocytoma, and melanoma.[1]

Copy number alteration of the interferon gene cluster in cancer

edit

A large individual patient data meta-analysis using 9937 patients obtained from cBioportal indicates that copy number alteration of the IFN gene cluster is prevalent among 24 cancer types. Notably deletion of this cluster is significantly associated with increased mortality in many cancer types particularly uterus, kidney, and brain cancers. The Cancer Genome Atlas PanCancer analysis also showed that copy number alteration of the IFN gene cluster is significantly associated with decreased overall survival. For instance, the overall survival of patients with brain glioma reduced from 93 months (diploidy) to 24 months. In conclusion, the copy number alteration of the IFN gene cluster is associated with increased mortality and decreased overall survival in cancer.[1]

Use of Interferon type I in therapeutics

edit

In cancer

edit

From the 1980s onward, members of type-I IFN family have been the standard care as immunotherapeutic agents in cancer therapy. In particular, IFNα has been approved by the US Food and Drug Administration (FDA) for cancer. To date, pharmaceutical companies produce several types of recombinant and pegylated IFNα for clinical use; e.g., IFNα2a (Roferon-A, Roche), IFNα2b (Intron-A, Schering-Plough) and pegylated IFNα2b (Sylatron, Schering Corporation) for treatment of hairy cell leukemia, melanoma, renal cell carcinoma, Kaposi's sarcoma, multiple myeloma, follicular and non-Hodgkin lymphoma, and chronic myelogenous leukemia. Human IFNβ (Feron, Toray ltd.) has also been approved in Japan to treat glioblastoma, medulloblastoma, astrocytoma, and melanoma.[1]

Combinational therapy with PD-1/PD-L1 inhibitors

edit

By combining PD-1/PD-L1 inhibitors with type I interferons, researchers aim to tackle multiple resistance mechanisms and enhance the overall anti-tumor immune response. The approach is supported by preclinical and clinical studies that show promising synergistic effects, particularly in melanoma and renal carcinoma. These studies reveal increased infiltration and activation of T cells within the tumor microenvironment, the development of memory T cells, and prolonged patient survival.[12]

In viral infection

edit

Due to their strong antiviral properties, recombinant type 1 IFNs can be used for the treatment for persistent viral infection. Pegylated IFN-α is the current standard of care when it comes to chronic Hepatitis B and C infection.[13]

In multiple sclerosis

edit

Currently, there are four FDA approved variants of IFN-β1 used as a treatment for relapsing multiple sclerosis.[14] IFN-β1 is not an appropriate treatment for patients with progressive, non-relapsing forms of multiple sclerosis.[15] Whilst the mechanism of action is not completely understood, the use of IFN-β1 has been found to reduce brain lesions, increase the expression of anti-inflammatory cytokines and reduce T cell infiltration into the brain.[16][17]

Side effects of type I interferon therapy

edit

One of the major limiting factors in the efficacy of type I interferon therapy are the high rates of side effects. Between 15% - 40% of people undergoing type 1 IFN treatment develop major depressive disorders.[18] Less commonly, interferon treatment has also been associated with anxiety, lethargy, psychosis and parkinsonism.[19] Mood disorders associated with IFN therapy can be reversed by discontinuation of treatment, and IFN therapy related depression is effectively treated with the selective serotonin reuptake inhibitor class of antidepressants.[20]

Interferonopathies

edit

Interferonopathies are a class of hereditary auto-inflammatory and autoimmune diseases characterised by upregulated type 1 interferon and downstream interferon stimulated genes. The symptoms of these diseases fall in a wide clinical spectrum, and often resemble those of viral infections acquired while the child is in utero, although lacking any infectious origin.[21] The aetiology is largely still unknown, but the most common genetic mutations are associated with nucleic acid regulation, leading most researchers to suggest these arise from the failure of antiviral systems to differentiate between host and viral DNA and RNA.[22]

Non-mammalian types

edit

Avian type I IFNs have been characterized and preliminarily assigned to subtypes (IFN I, IFN II, and IFN III), but their classification into subtypes should await a more extensive characterization of avian genomes.[citation needed]

Functional lizard type I IFNs can be found in lizard genome databases.[citation needed]

Turtle type I IFNs have been purified (references from 1970s needed). They resemble mammalian homologs.

The existence of amphibian type I IFNs have been inferred by the discovery of the genes encoding their receptor chains. They have not yet been purified, or their genes cloned.

Piscine (bony fish) type I IFN has been cloned first in zebrafish.[23][24] and then in many other teleost species including salmon and mandarin fish.[25][26] With few exceptions, and in stark contrast to avian and especially mammalian IFNs, they are present as single genes (multiple genes are however seen in polyploid fish genomes, possibly arising from whole-genome duplication). Unlike amniote IFN genes, piscine type I IFN genes contain introns, in similar positions as do their orthologs, certain interleukins. Despite this important difference, based on their 3-D structure these piscine IFNs have been assigned as Type I IFNs.[27] While in mammalian species all Type I IFNs bind to a single receptor complex, the different groups of piscine type I IFNs bind to different receptor complexes.[28] Until now several type I IFNs (IFNa, b, c, d, e, f and h) has been identified in teleost fish with as low as only one subtype in green pufferfish and as many as six subtypes in salmon with an addition of recently identified novel subtype, IFNh in mandarin fish.[25][26]

References

edit
  1. ^ a b c Razaghi A, Brusselaers N, Björnstedt M, Durand-Dubief M (September 2021). "Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy". Neoplasia. 23 (10): 1059–1068. doi:10.1016/j.neo.2021.08.004. PMC 8458777. PMID 34555656.
  2. ^ Schultz U, Kaspers B, Staeheli P (May 2004). "The interferon system of non-mammalian vertebrates". Developmental and Comparative Immunology. 28 (5): 499–508. doi:10.1016/j.dci.2003.09.009. PMID 15062646.
  3. ^ Samarajiwa SA, Wilson W, Hertzog PJ (2006). "Type I interferons: genetics and structure". In Meager A (ed.). The interferons: characterization and application. Weinheim: Wiley-VCH. pp. 3–34. ISBN 978-3-527-31180-4.
  4. ^ Zhou Q, Lavorgna A, Bowman M, Hiscott J, Harhaj EW (June 2015). "Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon". The Journal of Biological Chemistry. 290 (23): 14729–14739. doi:10.1074/jbc.M114.633065. PMC 4505538. PMID 25911105.
  5. ^ Wang YX, Xu WG, Sun XJ, Chen YZ, Liu XY, Tang H, Jiang CL (November 2004). "Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2". Journal of Neuroimmunology. 156 (1–2): 107–112. doi:10.1016/j.jneuroim.2004.07.013. PMID 15465601. S2CID 9067557.
  6. ^ Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (April 2010). "Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model". The Journal of Clinical Investigation. 120 (4): 1151–1164. doi:10.1172/JCI37223. PMC 2846036. PMID 20237412.
  7. ^ Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW (July 2011). "Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1". Journal of Virology. 85 (14): 6955–6962. doi:10.1128/JVI.00007-11. PMC 3126571. PMID 21593151.
  8. ^ Oritani K, Tomiyama Y (November 2004). "Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity". International Journal of Hematology. 80 (4): 325–331. doi:10.1532/ijh97.04087. PMID 15615256. S2CID 41691122.
  9. ^ Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog PJ (August 2004). "Characterization of the type I interferon locus and identification of novel genes". Genomics. 84 (2): 331–345. doi:10.1016/j.ygeno.2004.03.003. PMID 15233997.
  10. ^ a b Yang LM, Xue QH, Sun L, Zhu YP, Liu WJ (February 2007). "Cloning and characterization of a novel feline IFN-omega". Journal of Interferon & Cytokine Research. 27 (2): 119–127. doi:10.1089/jir.2006.0094. PMID 17316139.
  11. ^ Todd S, Naylor SL (July 1992). "New chromosomal mapping assignments for argininosuccinate synthetase pseudogene 1, interferon-beta 3 gene, and the diazepam binding inhibitor gene". Somatic Cell and Molecular Genetics. 18 (4): 381–385. doi:10.1007/BF01235761. PMID 1440058. S2CID 46694856.
  12. ^ Razaghi, Ali; Durand-Dubief, Mickaël; Brusselaers, Nele; Björnstedt, Mikael (2023). "Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1249330. ISSN 1664-3224. PMC 10484344. PMID 37691915.
  13. ^ Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004;24:97–104. [PubMed:15346252]
  14. ^ Filipi M, Jack S. Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update. Int J MS Care. 2020;22(4):165-172. doi:10.7224/1537-2073.2018-063
  15. ^ American Academy of Neurology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Neurology, retrieved August 1, 2013, which cites
    • La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G (January 2012). La Mantia L (ed.). "Interferon beta for secondary progressive multiple sclerosis". The Cochrane Database of Systematic Reviews. 1: CD005181. doi:10.1002/14651858.CD005181.pub3. PMID 22258960.
    • Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E (January 2010). Rojas JI (ed.). "Interferon Beta for primary progressive multiple sclerosis". The Cochrane Database of Systematic Reviews (1): CD006643. doi:10.1002/14651858.CD006643.pub3. PMID 20091602.
  16. ^ Kieseier  BC.  The  mechanism  of  action  of  interferon-beta  in  relapsing  multiple sclerosis. CNS Drugs. 2011;25:491-502
  17. ^ Kasper  LH,  Reder  AT.  Immunomodulatory  activity  of  interferon-beta.  Ann Clin Transl Neurol. 2014;1:622-631.
  18. ^ Lotrich FE. Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci. 2009;11(4):417-425. doi:10.31887/DCNS.2009.11.4/felotrich
  19. ^ Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105-123. doi:10.2165/00023210-200519020-00002
  20. ^ Pinto EF, Andrade C. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem. Curr Neuropharmacol. 2016;14(7):743-748. doi:10.2174/1570159x14666160106155129
  21. ^ d'Angelo DM, Di Filippo P, Breda L and Chiarelli F (2021) Type I Interferonopathies in Children: An Overview. Front. Pediatr. 9:631329. doi: 10.3389/fped.2021.631329
  22. ^ Crow, Yanick J.; Stetson, Daniel B. (2022). "The type I interferonopathies: 10 years on". Nature Reviews Immunology. 22 (8): 471–483. doi:10.1038/s41577-021-00633-9. PMC 8527296. PMID 34671122.
  23. ^ Altmann SM, Mellon MT, Distel DL, Kim CH (February 2003). "Molecular and functional analysis of an interferon gene from the zebrafish, Danio rerio". Journal of Virology. 77 (3): 1992–2002. doi:10.1128/jvi.77.3.1992-2002.2003. PMC 140984. PMID 12525633.
  24. ^ Lutfalla G, Roest Crollius H, Stange-Thomann N, Jaillon O, Mogensen K, Monneron D (July 2003). "Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: the class II cytokine receptors and their ligands in mammals and fish". BMC Genomics. 4 (1): 29. doi:10.1186/1471-2164-4-29. PMC 179897. PMID 12869211.
  25. ^ a b Laghari ZA, Chen SN, Li L, Huang B, Gan Z, Zhou Y, et al. (July 2018). "Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi". Developmental and Comparative Immunology. 84 (1): 94–108. doi:10.1016/j.dci.2018.02.008. PMID 29432791. S2CID 3455413. Archived from the original on 2020-06-17. Retrieved 2019-12-12.
  26. ^ a b Boudinot P, Langevin C, Secombes CJ, Levraud JP (November 2016). "The Peculiar Characteristics of Fish Type I Interferons". Viruses. 8 (11): 298. doi:10.3390/v8110298. PMC 5127012. PMID 27827855.
  27. ^ Hamming OJ, Lutfalla G, Levraud JP, Hartmann R (August 2011). "Crystal structure of Zebrafish interferons I and II reveals conservation of type I interferon structure in vertebrates". Journal of Virology. 85 (16): 8181–8187. doi:10.1128/JVI.00521-11. PMC 3147990. PMID 21653665.
  28. ^ Aggad D, Mazel M, Boudinot P, Mogensen KE, Hamming OJ, Hartmann R, et al. (September 2009). "The two groups of zebrafish virus-induced interferons signal via distinct receptors with specific and shared chains". Journal of Immunology. 183 (6): 3924–3931. doi:10.4049/jimmunol.0901495. PMID 19717522.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Interferon_type_I&oldid=1228960647"